EVALUATING EUROPEAN DATA SOURCES FOR ASSESSING REAL-WORLD EFFECTIVENESS OF NEW ANTI-DIABETIC DRUGS
Author(s)
Moïse P1, Andreykiv M2, Van Engen A2, Wimbush AJ3, Richards A3, Ploug UJ41Quintiles Global Consulting, Levallois-Perret, Ile-de-France, France, 2Quintiles Global Consulting, Hoofddorp, Noord-Holland, Netherlands, 3Novo Nordisk A/S, Zurich Oerlikon, Switzerland, 4Novo Nordisk A/S, Søborg, Denmark
OBJECTIVES: Real-world data sources (RWD) provide an important means for assessing the real clinical outcomes and value of newly marketed drugs. We aimed to develop a methodology to ascertain the feasibility of RWD in Europe to evaluate the effectiveness of new anti-diabetic drugs. METHODS: We searched a proprietary database of European RWDs and publicly available RWD initiatives (including TRANSFoRm and ISPOR international digest of databases). Additional RWDs were identified by literature search with PubMed and Google. A scoring algorithm was developed to prioritize RWDs on the basis of availability of relevant attributes. Each of 11 attributes was scored on a scale depending on the data to be captured and weighted based on the attribute’s importance. According to our scoring algorithm, a database could achieve a maximum of 70 points and a minimum of 50 points to be sufficient for evaluating effectiveness. RESULTS: We identified 42 RWDs with the potential for evaluating the effectiveness of anti-diabetic drugs and selected 25 for scoring after obtaining additional information. The scoring algorithm allowed us to prioritise RWDs based on 3 key attributes: 1) number of patients prescribed the drugs; 2) completeness of data for key parameters for which effectiveness was to be evaluated (e.g. lab and biometric values); 3) non-parameter attributes (country scope, ability to link to other RWDs, access and cost ). The algorithm yielded 16 RWDs meeting the predefined threshold of 50 points for evaluating effectiveness. However, further assessment indicated low feasibility of the 16 RWDs without linkage. CONCLUSIONS: We developed a unique and systematic approach to evaluating European RWDs; however, the main limitation of our methodology was the dependence on the responsiveness of the RWD holder. Further, the findings underscore limited feasibility for assessing outcomes in anti-diabetic drugs without database linkage, suggesting the need for improved RWDs in Europe.
Conference/Value in Health Info
2012-11, ISPOR Europe 2012, Berlin, Germany
Value in Health, Vol. 15, No. 7 (November 2012)
Code
PRM27
Topic
Real World Data & Information Systems
Topic Subcategory
Reproducibility & Replicability
Disease
Diabetes/Endocrine/Metabolic Disorders